Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28879162 | 0.91 | ADORA3 (0.52) | S1PR1S1PR3KIF11CASP3ADORA3 | |
| SCHEMBL29894012 | 0.88 | S1PR1 (0.46) | S1PR1S1PR3KIF11CASP3ADORA3 | |
| SCHEMBL8031410 | 0.88 | LMNA (0.62) | S1PR1S1PR3KIF11CASP3ADORA3 | |
| SCHEMBL7228785 | 0.85 | KIF11 (0.52) | S1PR1S1PR3KIF11ADORA3DPP4 | |
| SCHEMBL30862210 | 0.83 | KIF11 (0.58) | S1PR1S1PR3KIF11ADORA3DPP4 | |
| SCHEMBL4717972 | 0.82 | KIF11 (0.54) | S1PR1S1PR3KIF11CASP3GFER | |
| SCHEMBL22497605 | 0.82 | KIF11 (0.48) | S1PR1S1PR3KIF11CASP3ADORA3 | |
| SCHEMBL29414652 | 0.82 | KIF11 (0.48) | S1PR1S1PR3KIF11CASP3ADORA3 | |
| SCHEMBL17269505 | 0.81 | KIF11 (0.62) | S1PR1KIF11ADORA3DPP4LMNA | |
| SCHEMBL3561230 | 0.79 | ADORA2A (0.49) | S1PR1S1PR3KIF11LMNAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2009125870-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS. | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | WO | disclosed |
| EP-1028959-B1 | HERBICIDAL FURANYL- AND THIENYLOXYAZINES | BASF AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| EP-0723960-B1 | Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines | BASF AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| US-6121202-A | 2-((THIENYL OR FURYL) (OXY OR THIO))-PYRIDINE AND 6-((THIENYL OR FURYL) (OXY OR THIO))-PYRIMIDINE COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1028959-A1 | HERBICIDAL FURANYL- AND THIENYLOXYAZINES | AMERICAN CYANAMID COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024427-A1 | HERBICIDAL FURANYL- AND THIENYLOXYAZINES | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5849758-A | Herbicidal 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0823431-A1 | Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines | American Cyanamid Company (US) | 1998-02-11 | — | — | EP | disclosed |
| EP-0723960-A1 | Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines | American Cyanamid Company (US) | 1996-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | KCNJ2, KCNJ1, KCNJ11 | S1PR1 2995/4885S1PR3 2108/4885KIF11 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.